- Home
- KLTR vs SKYE Comparison
KLTR vs SKYE Comparison
Compare KLTR & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLTR
- SKYE
- Stock Information
- Founded
- KLTR 2006
- SKYE 2012
- Country
- KLTR United States
- SKYE United States
- Employees
- KLTR N/A
- SKYE N/A
- Industry
- KLTR EDP Services
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- KLTR Technology
- SKYE Health Care
- Exchange
- KLTR Nasdaq
- SKYE Nasdaq
- Market Cap
- KLTR 389.2M
- SKYE 94.0M
- IPO Year
- KLTR 2021
- SKYE N/A
- Fundamental
- Price
- KLTR $2.15
- SKYE $2.73
- Analyst Decision
- KLTR Buy
- SKYE Buy
- Analyst Count
- KLTR 2
- SKYE 6
- Target Price
- KLTR $2.25
- SKYE $18.67
- AVG Volume (30 Days)
- KLTR 704.1K
- SKYE 167.7K
- Earning Date
- KLTR 02-20-2025
- SKYE 02-09-2025
- Dividend Yield
- KLTR N/A
- SKYE N/A
- EPS Growth
- KLTR N/A
- SKYE N/A
- EPS
- KLTR N/A
- SKYE N/A
- Revenue
- KLTR $177,586,000.00
- SKYE N/A
- Revenue This Year
- KLTR $3.34
- SKYE N/A
- Revenue Next Year
- KLTR $1.88
- SKYE N/A
- P/E Ratio
- KLTR N/A
- SKYE N/A
- Revenue Growth
- KLTR 1.62
- SKYE N/A
- 52 Week Low
- KLTR $0.76
- SKYE $2.25
- 52 Week High
- KLTR $2.82
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- KLTR 47.46
- SKYE 37.40
- Support Level
- KLTR $1.93
- SKYE $2.31
- Resistance Level
- KLTR $2.82
- SKYE $3.04
- Average True Range (ATR)
- KLTR 0.18
- SKYE 0.30
- MACD
- KLTR -0.05
- SKYE 0.07
- Stochastic Oscillator
- KLTR 24.72
- SKYE 44.68
About KLTR Kaltura Inc.
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and at school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments which are Enterprise, Education, and Technology, and Media and Telecom. The majority of the revenue is derived from Enterprise, Education & Technology. The majority of the revenue is earned from the United States.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.